SuperX Ltd, a Cambridge, UK-based biopharmaceutical company, completed an $11m Series A funding.
The round was led by Medicxi with participation from Johnson & Johnson Innovation – JJDC, Inc., the corporate venture arm of Johnson & Johnson. Kevin Johnson, Partner at Medicxi, will serve as Chairman of the SuperX Board.
The company intends to use the funds to further develop antibodies with anticoagulant properties.
Founded by David Grainger, CEO, Trevor Baglin, Chief Medical Officer, Jim Huntington, Chief Scientific Officer, Bob Schroff, operations chief, and Jo Davies, intellectual property manager, SuperX will operate as a virtual biotechnology company, with no internal operations, using an established network of out-sourced drug discovery and development providers, many of which are co-located on the Babraham Research Campus, just south of Cambridge, UK.
FinSMEs
16/02/2017